ACTEMRA for Intravenous Infusion 80mg (アクテムラ点滴静注用80mg)

Country: Ġappun

Lingwa: Ingliż

Sors: すりの適正使用協議会 RAD-AR Council, Japan

Ingredjent attiv:

Tocilizumab(genetical recombination)

Disponibbli minn:

Chugai Pharmaceutical Co., Ltd.

INN (Isem Internazzjonali):

Tocilizumab(genetical recombination)

Għamla farmaċewtika:

injection

Fuljett ta 'informazzjoni

Drug Information Sheet("Kusuri-no-Shiori")
Injection
Revised: 09/2023
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
ACTEMRA FOR INTRAVENOUS INFUSION 80MG
ACTIVE INGREDIENT:
Tocilizumab(genetical recombination)
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine improves joint pain/swelling and general symptoms
associated with rheumatoid
arthritis, polyarticular-course juvenile idiopathic arthritis (pJIA),
systemic juvenile idiopathic
arthritis (sJIA) and prevents progression of joint destruction in
rheumatoid arthritis, by
suppressing the actions of Interleukin-6 (IL-6). This medicine
improves fever, joint
pain/swelling and rash associated with Adult Still's disease,
conditions (e.g. general malaise)
and laboratory findings (e.g. increased C-reactive protein, anemia)
associated with
Castleman's disease, fever and general dullness symptoms associated
with cytokine release
syndrome (CRS). This medicine also improves symptoms associated with
SARS-CoV-2
pneumonia.
It is usually used for treatment of rheumatoid arthritis,
polyarticular-course juvenile idiopathic
arthritis, systemic juvenile idiopathic arthritis, Adult Still's
disease, Castleman's disease,
cytokine release syndrome induced by malignant tumor treatment and
SARS-CoV-2
pneumonia (limited to patients requiring oxygen intervention).
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have bacterial/viral infection.
If you are a hepatitis B virus carrier or have a history of hepatitis
B